Stoke Therapeutics (STOK) Net Cash Flow (QoQ) (2018 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Net Cash Flow (QoQ) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -161.33% |
| Mar 31, 2026 | 8,911.99% |
| Dec 31, 2025 | 104.55% |
| Sep 30, 2025 | 89.53% |
| Jun 30, 2025 | -218.06% |
| Mar 31, 2025 | 773.36% |
| Dec 31, 2024 | 49.83% |
| Sep 30, 2024 | -391.78% |
| Jun 30, 2024 | 215.82% |
| Mar 31, 2024 | -977.88% |
| Dec 31, 2023 | 170.33% |
| Sep 30, 2023 | -221.03% |
| Jun 30, 2023 | -97.76% |
| Mar 31, 2023 | 47,889.38% |
| Dec 31, 2022 | -99.65% |
| Sep 30, 2022 | 379.04% |
| Jun 30, 2022 | 73.09% |
| Mar 31, 2022 | -1,316.88% |
| Dec 31, 2021 | 78.04% |
| Sep 30, 2021 | 80.15% |